enzo
launches
portable
microplate
reader
use
elisa
assay
kits
simplify
laboratory
workflow
powerful
precise
compact
instrument
enables
enzo
offer
complete
solution
advance
drug
discovery
microplate
reader
retrofitted
clinical
testing
urgent
care
facilities
hospitals
physicians
offices
new
york
ny
globe
newswire
enzo
biochem
nyse
enz
leading
biosciences
diagnostics
company
announced
today
commercial
launch
small
portable
microplate
reader
use
company
immunoassays
ultimately
molecular
diagnostics
providing
new
opportunities
medicine
affordable
device
enables
enzo
offer
complete
solution
academic
cro
industrial
customers
enzo
provider
elisa
immunosorbent
assay
assay
kits
including
hundreds
highly
sensitive
elisas
manufactures
advanced
design
technology
enzo
compact
microplate
reader
makes
possible
deliver
precise
accurate
results
together
enzo
proprietary
software
device
option
wide
variety
applications
based
miniaturization
enzo
assays
tests
include
metabolites
hormones
pregnancy
proteins
inflammatory
cytokines
protein
characterization
support
instrument
manufacturing
company
enzo
portable
reader
enables
lab
work
executed
outside
traditional
research
facilities
rely
shared
instrumentation
researchers
lab
professionals
dedicated
personal
device
fit
space
needs
convenience
accessibility
previously
available
handheld
instrument
size
average
benchtop
plate
reader
allowing
fit
laboratory
setting
saving
bench
space
providing
new
levels
flexibility
portability
extended
facilities
allow
physicians
provide
molecular
testing
including
assays
viral
detection
sexually
transmitted
diseases
compact
technology
enables
utilization
instrument
new
locations
technology
testing
move
centralized
complex
clinical
labs
closer
patient
care
simplifies
testing
procedures
opens
opportunity
shift
testing
hands
licensed
medical
technicians
healthcare
professionals
operating
nearer
patients
instances
even
patients
access
testing
continues
grow
technological
advances
clinical
diagnostic
testing
drive
miniaturization
complex
devices
computers
moved
mainframes
powerful
portable
handheld
devices
happening
within
clinical
diagnostic
testing
industry
reduced
complexity
provides
high
quality
precise
testing
capabilities
available
broader
range
healthcare
professionals
involved
patient
management
whether
sitting
urgent
care
facility
doctor
office
hospital
bedside
said
kara
cannon
chief
commercial
officer
enzo
testing
market
currently
valued
globally
potential
aggressively
expand
many
testing
needs
widely
available
including
significant
portion
immunoassay
testing
market
added
cannon
common
clinical
immunoassay
tests
vitamin
testing
inflammation
analysis
currently
performed
regularly
clinical
central
testing
lab
licensed
medical
technologists
using
large
complex
instrumentation
unlike
lateral
flow
assays
small
yet
powerful
system
sacrifice
sensitivity
convenience
allows
enzo
corporate
vision
addresses
new
opportunities
expansion
growth
within
products
services
added
cannon
serving
markets
including
laboratories
market
launch
important
step
extending
offerings
beyond
central
laboratory
enabling
physicians
provide
clinical
testing
office
urgent
care
facility
treatment
future
enzo
anticipates
launching
isothermal
testing
platform
enabling
constant
temperature
eliminating
need
thermal
cycler
learn
enzo
plate
readers
full
range
enzo
assays
researchers
visit
enzo
biochem
enzo
biochem
pioneer
molecular
diagnostics
leading
convergence
clinical
laboratories
life
sciences
intellectual
property
development
unique
diagnostic
platform
technologies
provide
numerous
advantages
previous
standards
global
company
enzo
biochem
utilizes
teams
develop
deploy
products
systems
services
meet
rapidly
growing
needs
health
care
today
future
underpinning
enzo
biochem
products
technologies
broad
deep
intellectual
property
portfolio
patent
coverage
across
number
key
enabling
technologies
statements
except
historical
information
matters
discussed
release
may
considered
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
include
declarations
regarding
intent
belief
current
expectations
company
management
including
related
cash
flow
gross
margins
revenues
expenses
dependent
number
factors
outside
control
company
including
inter
alia
markets
company
products
services
costs
goods
services
expenses
government
regulations
litigation
general
business
conditions
see
risk
factors
company
form
fiscal
year
ended
july
investors
cautioned
statements
guarantees
future
performance
involve
number
risks
uncertainties
could
materially
affect
actual
results
company
disclaims
obligations
update
statement
result
developments
occurring
date
release
contact
enzo
biochem
david
bench
cfo
dbench
media
marisa
monte
berry
company
public
relations
mmonte
investors
jeremy
feffer
lifesci
advisors
llc
jeremy
steve
anreder
anreder
company
